anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Disclosed are a viscosity-standardized combination of solutions and a method of using the solutions for the diagnosis of dysphagia and for radiographic imaging of the oropharynx. This invention is directed to a standardized combination of edible solutions for evaluating human subjects for the presence of dyshagia. Because the solutions have a standard and known viscosity, they promote the systematic study and treatment of swallowing disorders. The combination comprises three solutions: the first a "thin" composition, the second a "nectar thick" composition and the third a"honey thick" composition. The utilities of the subject compositions and methods are several-fold. A primary utility is that by using standardized compositions, consistency in treating dysphagia is promoted. Rather than supplying patients an arbitrarily thickened food or X-ray imaging product, the patient is supplied a composition of known viscosity. The patient's ability to swallow the composition properly i studies (one using the nectar-thick composition, the other using the honey-thick composition) to be compared and contrasted. Moreover, it allows the results from different patients to be compared directly, without variations in viscosity of the imaging agent introducing uncontrolled variables into the comparison.
An attachable monitoring device includes a battery unit, a flexible printed circuit board and a physical condition sensor and an adhesive. The battery unit includes a top surface, a bottom surface and a plurality of side surfaces connecting the top surface and the bottom surface. The flexible printed circuit board is bent to cover the top surface, the bottom surface and one of the side surfaces and electrically connected to the battery unit. The flexible printed circuit board includes a printed antenna printed on a first outer surface of the flexible printed circuit board. The physical condition sensor is disposed on a second outer surface of the flexible printed circuit board opposite to the first outer surface. The physical condition sensor includes a sensing region for contacting a user to detecting a physical-condition signal of the user. The adhesive is disposed on the flexible printed circuit board for being attached to the user.
The present invention relates generally to risk prediction for patient management, and in particular to comprehensive risk prediction for patient management of patients suspected or identified as having COVID-19 (2019 coronavirus disease). The present invention provides systems and methods for predicting the risk of a medical event associated with assessing or treating a patient's disease. Input medical imaging data and patient data of a patient are received. The input medical imaging data includes an abnormal pattern associated with the disease. Imaging features are extracted from the input medical imaging data using a trained machine learning based feature extraction network. One or more of the extracted imaging features are normalized. One or more normalized extracted imaging features and patient data are encoded as features using a trained machine learning based encoder network. The risk of a medical event associated with assessing or treating a patient's disease is predicted based on the encoded features.
The present invention discloses a perfume spraying liquor which belongs to an oral cavity health physic liquor. The perfume spraying liquor is prepared by mixing a water-leach liquor and an alcohol solution with the volume ratio of 1: 2, wherein the leached substances of the water-leach liquor comprises 3 to 6g of kudzuvine root, 0.6 to 2g of cassia twig, 1 to 5g of green tea, 1 to 6g of clore, 1 to 4g of eupatorium, 1 to 3g of herb agastachis, 3.5 to 6.5g of haichow elsholtzia herb, 1 to 3.5g of manchurian wildginger and 5 to 10g of honeysuckle flower. The water-leach liquor is prepared by 18g of mixture of the leached substances being leached in every 100 milliliters of distilled water. The alcohol solution has the concentration that every 100 milliliters of 50% alcohol contains 6 to 98g mg of vanillin, 0.4 to 1g of peppermint oil and 0.4 to 1g of crystallisation borneol. The vanillin is 3-methoxy-4-hydroxybenzaldehyde. The present invention has the advantages of no generation of mistake easting or mistake gulp, no residue and no environmental pollution, and is particularly suitable for cleaning the oral cavity and eliminating the abnormal flavour of the oral cavity.
Food effect Cohort 1: The dose of ND-003 tablets will be determined based on the results of the SAD and MAD. Participants will be orally administered in fasting condition in day 1 and then in fed condition in day 8.
There are variations in individual eltrombopag concentrations that may impact efficacy and adverse drug reactions (ADRs) in paediatric immune thrombocytopenia (ITP). To solve this problem, we tailored the eltrombopag dosage refer to concentration, then followed up to assess concentration value in paediatric ITP. This is a single-centre, prospective, observational study. The eltrombopag dosage was adjusted, and children were divided into three groups: the maintenance, discontinuation, and increase groups. Concentration and other data were compared to explore concentration value in guiding the individualized treatment of paediatric ITP. Thirty-nine patients were enrolled, including 23 in the maintenance group, 3 in the discontinued group and 13 in the increase group. 3 patients discontinued eltrombopag due to ADRs, which was significantly higher than patients in the maintenance group (t = 3.606, p = 0.001). In all, 13 patients increased their dosage due to poor response, whose concentration and platelet count were significantly lower than patients in the maintenance group (t = 2.461, p = 0.019; t = 4.633, p < 0.001). Two months after the increase, the number of patients reaching CR and R respectively increased by 2 and 3, while the median platelet count was significantly raised (Z = -2.411, p = 0.016). Concentration could be used as a reference index for the individualized treatment of eltrombopag in paediatric ITP.
In the meta-analysis, we evaluated the efficacy of placing drainage channels following single- or double-level spine surgery in order to decrease the incidence of postoperative injury. We conducted the analysis with the help of four databases: PubMed, Embase, Cochrane Library and Web of Science. A review of related studies was carried out after evaluating the quality of the literature against the classification and exclusion criteria set for the trial. Calculation of 95% CI, OR and MD was performed with fixed-effect models. A meta-analysis of the data was carried out with RevMan 5.3. Meta-analyses of randomized controlled trial (RCT) did not indicate that there were a statistically significantly different incidence of postoperative wound infections among those who received drainage compared to those who did not receive drainage (OR, 2.29; 95% CI, 0.50, 10.41 p = 0.28). Moreover, there were no statistically significant differences in post-operation hematoma (OR, 1.20; 95% CI, 0.27, 5.28 p = 0.81) and visual analogue scale score (MD, -0.01; 95% CI, -1.34, 1.33 p = 0.99). Thus, placing drainage in short-levels of spine operation did not significantly influence the outcome of postoperative wound complications. Nevertheless, because of the limited sample size chosen for this meta-analysis, caution should be exercised when treating these data. More high-quality RCT trials with a large number of samples are required to confirm the findings.
Improvements in mining information from patient records and/or use of such mined information are provided. A scheduled appointment is identified. In response, the patient record is mined to identify any possible lack of adherence. A form requiring authorization and including a clinical action or prescription is generated to address, at least in part, the lack of adherence. Contact with a patient is initiated by a processor, at least in part, in response to a lack of adherence. A request for documentation is generated in response to mining indicating an inadequate probability of adherence to a guideline. During real-time, additional information to be obtained which may alter a probability is suggested.
BACKGROUND: A common approach to attempt to reduce maternal morbidity from hemorrhage is to recognize patients at increased risk, and to make advance preparations for possible blood transfusion in these patients. Preparation may consist of a hold clot, type, and screen, or crossmatch. Most hospitals, including ours, have pathways or guidelines that lay out which of these preparations should be made at the time a patient is admitted to labor and delivery. These are often based on risk factors for hemorrhage but do not take into account the probability that transfusion will be needed. The cost-effectiveness of performing a type and screen or routine crossmatch on patients admitted for delivery has been questioned. Several studies have shown that the chance of transfusions in individuals giving birth is very low. In terms of the need for routine blood preparation, the need for urgent transfusion is most relevant. This has not been included in studies of transfusion rates.
OBJECTIVE: The purpose of this study was to quantify the relative importance of risk factors present on admission for needing a blood transfusion and to develop a formula to define each individual's risk. This could then be used to decide an appropriate level of initial blood preparation for patients at different risk levels.
STUDY DESIGN: Risk factors for hemorrhage and the level of transfusion preparation were extracted from the medical records of a cohort of 89,881 patients delivering in an 18-hospital healthcare system over 40 months. We tabulated the number who required at least one RBC transfusion and the number needing an urgent transfusion-defined as receiving blood during labor or within 4 hours after delivery. Odds ratios for requiring a transfusion were calculated for each risk factor. We then calculated the probability of needing a transfusion for each patient based on their risk factor profile.
RESULTS: A total of 643 patients had any transfusion during their hospitalization (0.72% of deliveries), and 311 had an urgent transfusion (0.35% of deliveries). The calculated probability of needing a transfusion was less than 1% in 87.8% of patients and was greater than 5% in 1.2% of patients. The chance of needing a transfusion was highest for placenta accreta spectrum, admission Hgb <8.0, and placenta previa. A second tier of risk factors included abruption, bleeding with no specific diagnosis, and Hgb between 8.0 and 10.0.
CONCLUSION: In our cohort, very few patients received a transfusion. Applying a formula derived from patient-specific risk factors, we found that almost all patients have a very low probability of needing a transfusion, especially an urgent transfusion. Based on these results, we suggest that a hold clot be used except for the highest-risk patients or in settings with barriers to procuring blood in the rare case of urgent transfusion need. Making this change would greatly reduce hospital blood bank charges.
The role of Human papillomavirus (HPV) infection in esophageal squamous cell carcinoma (ESCC) is a topic of ongoing debate. This study used two screening approaches to look for evidence of HPV infection in esophageal squamous cell carcinoma. We initially checked for HPV infection in a randomly selected group of 53 ESCC cases. We did not detect any tumors positive for high-risk HPV. However, during clinical practice, we identified an HPV-positive ESCC in the distal esophagus, which tested positive for HPV16. This index case was TP53 wild-type, as determined by next-generation DNA sequencing (NGS). Since TP53 mutations are rare in other HPV-driven cancers, we improved our screening method by limiting our screen to a subset of ESCC cases without TP53 mutations. A second screen of 95 ESCCs (from 93 patients) sequenced by NGS revealed an additional 7 ESCCs with TP53 wild-type status (7.3% of the total). Of the 7 cases, 2 cases were found to be high-risk HPV positive. Both patients also tested positive for circulating cell-free HPV DNA and had a complete response to neoadjuvant chemoradiation. The index patient had microscopic residual tumor following neoadjuvant therapy. The patient underwent adjuvant immunotherapy and remained disease free after 22 months of surveillance. This study affirms the transcriptionally active status of high-risk HPV in a minority of ESCC patients in North America.
Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include \~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio \<1.5 and fat intake set at \~30% of the total energy intake. Dietary fat sources will focus on monounsaturated and polyunsaturated fats, e.g., plant oils and nuts; dietary carbohydrate sources will emphasize whole grains, fruits, vegetables, and legumes; and dietary protein sources will include lean meats, fish, chicken, eggs, and nonfat dairy foods, e.g., fat-free milk and low-fat cheese, consistent with American Diabetes Association and Institute of Medicine guidelines. All LC-HP meals will be provided by UAB Center for Clinical and Translational Sciences (CCTS) Bionutrition Unit and delivered to participants' homes 3 times/week (a sample menu is included in Appendix J). Every delivery will include breakfast, lunch, dinner, and snacks for 2 to 3 days.
PCT No. PCT/GB92/00359 Sec. 371 Date Aug. 26, 1993 Sec. 102(e) Date Aug. 26, 1993 PCT Filed Feb. 28, 1992 PCT Pub. No. WO/9215314 PCT Pub. Date Sep. 17, 1992.A process is provided which is suitable for the preparation of herbal compositions for the treatment of skin disorders such as eczema and psoriasis. The process comprises preparing an extract or extracts of herbs which provide an anti-inflammatory agent, an adrenocortical stimulant and a cortisol protecting agent by steam distillation and decoction and then treating the extracts to reduce the polysaccharide and/or sugar content. This is achieved by fermentation or enzymic action or by extraction with a solvent having a polarity in the range E DEG  0.4 to 0.95 or by precipitation with an inorganic compound and/or colloid or by a combination of two or more of the above. As a final concentration step, the material is further purified by extraction with a solvent having a polarity in the range mentioned above. The reduction of the sugar/polysaccharide content greatly improves the handling characteristics of the extract which can be dried to a free flowing powder. Tablets and capsules for oral administration can be prepared from the extract and it is also suitable for the preparation of topical compositions.
Background Information: Everyday pain is common in children with intellectual/developmental disabilities (I/DD). Inadequately managed pain in this population is a common problem, and this is likely due to these children's inability to communicate pain effectively. Unfortunately, many of these children are unable to accurately self-report or effectively communicate the pain experience. Thus, caregivers are often responsible for assessing their pain. Research has focused on professionals and parents, but it is also common for children with I/DD to receive care from others including respite workers. The investigators recently found a difference between pain beliefs held by respite workers and individuals with little to no experience with this population. Specifically, respite workers believed that a significantly larger percentage of children with severe I/DD sensed less pain than typically developing children. This is contrary to research suggesting that children with I/DD have similar pain perception but communicate it differently (e.g., through idiosyncratic behaviours). Thus, it is possible that respite workers miss critical cues when children with I/DD are in pain. As such, the investigators have developed and successfully piloted a pain training program targeted to respite workers who support children with I/DD. This program demonstrated initial success in improving respite workers' pain-related knowledge, as well as their perceptions of the feasibility of and their own confidence and skill in pain assessment and management with this population of children.

Within a randomized control trial, the objectives of this study are to further test the effectiveness of the Let's Talk About Pain respite worker training program on respite workers' (a) pain-related knowledge, (b) self-rated perceptions of the feasibility of and their own confidence and skill in pain assessment and management, and (c) use of pain assessment and management strategies specific to children with I/DD in respite settings. Participants will complete questionnaires immediately before and after provision of a pain training (or control training). Approximately one month after the training, participants will complete these questionnaires for a third time and participate in a focus group regarding their pain assessment and management strategy use.

The long term objectives of this line of research are to: 1) increase pain assessment and management abilities of respite workers, and, consequently, 2) decrease levels of suffering and ill-managed pain in children with I/DD.
Part 2 includes women with early breast cancer. Cohorts B and C will be enrolled if FDC of pertuzumab and trastuzumab is feasible. Participants will receive pertuzumab and trastuzumab (600 mg) SC; both agents administered in one injection (co-mixed). The dose of pertuzumab will be identified during Part 1.
For the diagnosis of neuroblastoma with bone marrow metastasis, the medical practices including as follows: bone marrow biopsy, bone marrow cytology of aspiration smear, flow cytometry and positron emission tomography-computed tomography(PET-CT). Bone marrow biopsy or smear analysis may reveal characteristic NB cells. Flow cytometry may detect NB cells with phenotype of cluster of differentiation antigen 45(CD45)-/cluster of differentiation antigen 56(CD56)+/cluster of differentiation antigen 81(CD81)+/GD2 ganglioside (GD2)+. PET/CT imaging reveal the metastatic NB cells in term of metabolic activity and spatial distribution of metastatic involvement. A positive result from any of these methods is sufficient for diagnosed as NB with bone marrow metastasis.
Turmeric gel will be self-prepared at the Institute of Microbiology and Molecular Genetics, Punjab University, Lahore. 2kgs of Turmeric rhizomes were purchased from a local market in Lahore and verified by a taxonomist, Botany Department, Government College University, Lahore (voucher number: GC.Herb.Bot.3693). Approximately 170g powder along with 550ml distilled water will be taken in a Soxhlet extractor for 96 hours and then filtered repeatedly through Whatman No.1 filter paper. The obtained filtrate will then be mixed with 6% Sodium Carboxy-Methyl Cellulose (NaCMC) (Genevex Chem, Hyderabad, India) to form gel. Four Vitamin C grounded tablets (Wilson's Vitamin C, Wilson's Healthcare, Islamabad, Pakistan) and twelve Vitamin E capsules (Evion, Martin Dow pharmaceuticals, Ltd. Karachi, Pak) will then be added in 100g of gel as antioxidants.
PURPOSE: A makeup cosmetic composition is provided to stabilize a large amount of polyols and to ensure long-lasting moisturizing. CONSTITUTION: A makeup cosmetic composition contains polyglycerin-modified dimethicone. The polyglycerin-modified dimethicone is branched type or cross-linked polymer type. The polyglycerin-modified dimethicone includes polyglyceryl-3 disiloxandimethicone, polyglyceryl-3 polydimethyl disiloxy ethyl dimethicone, lauryl polyglyceryl-3 polydimethyl disiloxyethyl dimethicone, dimethicone/polyglycrine-3 cross polymers or lauryl dimethicone/polyglycerin-3 crosspolymer. The composition further contains 10-80 wt% of polyol. The polyol includes glycerin, butylene glycol, propylene glycol, dipropylene glycol, pentylene glycol, hexylene glycol, polyethylene glycol, or sorbitol.
Ticagrelor is a novel, direct-acting, reversibly binding P2Y12 receptor antagonist. When related with clopidogrel, ticagrelor exhibits a more potent and more predictable antiplatelet effect with a faster onset and offset of action. Current guidelines give a recommendation on the use of dual antiplatelet therapy support ticagrelor 90 mg twice daily over clopidogrel 75 mg daily in addition to aspirin in CAD patients. However, increasing evidence showed ticagrelor increased the risk of bleeding. Recent studies showed that P2Y12 inhibitor monotherapy still maintain antiischemic efficacy while reducing the bleeding risk compared with DAPT. So the investigators performed this randomized, single-blind, crossover clinical trial to observe the effects of standard-dose ticagrelor and standard-dose clopidogrel on platelet reactivity in Chinese patients with stable CAD.
Hematuria, renal colic, costovertebral pain, and formation of uric acid stones associated with the use of probenecid and colchicine in gouty patients may be prevented by alkalization of the urine and a liberal fluid intake (see DOSAGE AND ADMlNlSTRATION). In these cases when alkali is administered, the acid-base balance of the patient should be watched.

Use with caution in patients with a history of peptic ulcer. 

Probenecid and colchicine has been used in patients with some renal impairment but dosage requirements may be increased. Probenecid and colchicine may not be effective in chronic renal insufficiency particularly when the glomerular filtration rate is 30 mL/minute or less.

A reducing substance may appear in the urine of patients receiving probenecid. This disappears with discontinuance of therapy. Suspected glycosuria should be confirmed by using a test specific for glucose.

Adequate animal studies have not been conducted to determine the carcinogenicity potential of probenecid or this drug combination. Since colchicine is an established mutagen, its ability to act as a carcinogen must be suspected and administration of probenecid and colchicine should involve a weighing of the benefit-vs-risk when long-term administration is contemplated.
The present invention is related generally to measurement of body fluid volumes in an animal subject. The body fluid volumes of interest include extracellular fluid volume (ECFV), total vascular plasma volume (TVPV) and interstitial fluid volume (IFV). The methods are especially beneficial for subjects suffering from renal failure and particularly those undergoing renal dialysis. ECFV can be measured by administering a first molecule which is non-metabolized and permeable to vessel walls of the vascular system wherein the first molecule is distributed within the total vascular space as well as the interstitial space. TVPV can be measured by administering a second molecule which is non-metabolized and impermeable to vessel walls of the vascular system wherein the second molecule is distributed within only the vascular space. IFV can then be calculated using the equation IFV=ECFV−TVPV.